Fig 1.
A. Survival curve DFS of No-Special Type BC and Special Type BC subgroups using Kaplan-Meier method. B. Survival curve of OS times of No-Special Type BC and Special Type BC subgroups using Kaplan-Meier method.
Table 1.
DFS and OS times, comparative log-rank test, p-value values of no-special type BC and special type BC subgroups obtained using Kaplan-Meier method.
Fig 2.
A. Survival curve of DFS times of No-Special Type BC and No-Lobular Special Type BC and Invasive Lobular Special Type BC subgroups using Kaplan-Meier method. There are 2066 patients at the beginning of the DFS curve, as 91 of a total of 2157 breast cancer patients had metastatic presentation at baseline. B. Survival curve of OS times of No-Special Type BC and No-Lobular Special Type BC and Invasive Lobular Special Type BC subgroups using Kaplan-Meier method.
Table 2.
DFS and OS times, comparative log-rank test, p-value values of no-special type BC and no-Lobular Special Type BC, ILC subgroups obtained using Kaplan-Meier method.
Fig 3.
Subgroup distribution according to histopathological subgroup differentiation.
A. No-Special Type BC, B. Invasive Lobular Special Type BC, C. No-Lobular Special Type BC.
Table 3.
Distribution of patient characteristics.
Table 4.
Univariate analysis results affecting DFS.
Table 5.
Multivariate analysis results affecting DFS.
Table 6.
Univariate analysis results affecting OS.
Table 7.
Multivariate analysis results affecting OS.